BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $40,924,158 | -22.6% | 601,207 | -7.2% | 0.01% | -16.7% |
Q2 2023 | $52,871,915 | +27.0% | 647,702 | +15.5% | 0.01% | +20.0% |
Q1 2023 | $41,621,000 | +96461.7% | 560,985 | +7.9% | 0.01% | -16.7% |
Q4 2022 | $43,103 | -99.9% | 520,083 | +259.5% | 0.01% | 0.0% |
Q3 2022 | $41,084,000 | -21.7% | 144,667 | -4.4% | 0.01% | -14.3% |
Q2 2022 | $52,457,000 | -20.6% | 151,328 | -0.8% | 0.01% | -12.5% |
Q1 2022 | $66,058,000 | -20.7% | 152,549 | -5.3% | 0.01% | -20.0% |
Q4 2021 | $83,340,000 | -20.8% | 161,091 | -25.8% | 0.01% | -23.1% |
Q3 2021 | $105,240,000 | +7.6% | 217,184 | -0.1% | 0.01% | +8.3% |
Q2 2021 | $97,851,000 | +22.6% | 217,322 | +4.0% | 0.01% | +9.1% |
Q1 2021 | $79,823,000 | +59.6% | 208,998 | +32.7% | 0.01% | +57.1% |
Q4 2020 | $50,008,000 | +79.7% | 157,477 | +39.6% | 0.01% | +40.0% |
Q3 2020 | $27,828,000 | +7.9% | 112,777 | +15.5% | 0.01% | 0.0% |
Q2 2020 | $25,782,000 | +85.1% | 97,633 | +32.9% | 0.01% | +66.7% |
Q1 2020 | $13,930,000 | -6.5% | 73,462 | +8.2% | 0.00% | 0.0% |
Q4 2019 | $14,904,000 | +7.9% | 67,900 | -3.8% | 0.00% | 0.0% |
Q3 2019 | $13,818,000 | +59.3% | 70,614 | +68.0% | 0.00% | +50.0% |
Q2 2019 | $8,676,000 | -2.6% | 42,036 | -6.3% | 0.00% | 0.0% |
Q1 2019 | $8,909,000 | +43.0% | 44,864 | +4.2% | 0.00% | +100.0% |
Q4 2018 | $6,230,000 | -60.3% | 43,043 | -44.0% | 0.00% | -66.7% |
Q3 2018 | $15,686,000 | +55.1% | 76,856 | +12.4% | 0.00% | +50.0% |
Q2 2018 | $10,116,000 | -2.3% | 68,376 | -0.2% | 0.00% | 0.0% |
Q1 2018 | $10,353,000 | +85.4% | 68,545 | +59.1% | 0.00% | +100.0% |
Q4 2017 | $5,583,000 | +3672.3% | 43,094 | +3412.1% | 0.00% | – |
Q3 2017 | $148,000 | -79.1% | 1,227 | -79.7% | 0.00% | – |
Q2 2017 | $709,000 | +786.2% | 6,034 | +665.7% | 0.00% | – |
Q1 2017 | $80,000 | -88.3% | 788 | -88.1% | 0.00% | – |
Q4 2016 | $681,000 | +229.0% | 6,619 | +251.7% | 0.00% | – |
Q3 2016 | $207,000 | -51.2% | 1,882 | -50.0% | 0.00% | – |
Q2 2016 | $424,000 | +41.3% | 3,765 | +19.0% | 0.00% | – |
Q1 2016 | $300,000 | +87.5% | 3,164 | +78.6% | 0.00% | – |
Q4 2015 | $160,000 | -42.2% | 1,772 | -40.9% | 0.00% | – |
Q3 2015 | $277,000 | -83.6% | 2,998 | -82.2% | 0.00% | – |
Q1 2015 | $1,686,000 | -62.8% | 16,806 | -65.8% | 0.00% | -100.0% |
Q4 2014 | $4,537,000 | – | 49,099 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |